47 results
8-K
EX-99.1
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
29 Feb 24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
8:03am
attributable to the gross proceeds of at-the-market offerings, partially offset by cash used in the Company’s operations.
Matthias Bodenstedt, Chief Financial
424B3
7ykyf
14 Nov 22
Prospectus supplement
8:32am
S-8
EX-10.4
avncqw4 44fga3d
30 Sep 22
Registration of securities for employees
4:06pm
424B3
l3ebp0uiqta16asimu44
12 Aug 22
Prospectus supplement
4:52pm
8-K/A
EX-99.1
ce4sftt2herrhm8cccm
16 May 22
Completion of Acquisition or Disposition of Assets
4:10pm
8-K/A
EX-99.3
f2fb0a0p
16 May 22
Completion of Acquisition or Disposition of Assets
4:10pm